{
  "hash": "93bd434a36fcb87869bcffb267d7c3bc",
  "result": {
    "markdown": "---\ntitle: \"Melanoma tumour thickness in Norway\"\nsubtitle: \"An analysis of survival trend,<br>1983â€“2019\"\nauthor: \"Raju Rimal\"\ndate: \"13 June, 2023\"\ninstitute: \"Department of Biostatistics<br>University of Oslo\"\ncode-overflow: scroll\ndate-format: \"DD MMMM YYYY\"\nbibliography: References.bib\ncitations-hover: true\nknitr:\n  opts_chunk: \n    collapse: true\n    comment: \"#>\" \nexecute: \n  echo: false\n  warning: false\nformat: \n  revealjs:\n    transition: none\n    background-transition: none\n    template-partials:\n      - title-slide.html\n    theme: [default, custom.scss]\n    logo: Images/Logos/UiO-Logo.png\n    title-slide-attributes:\n      data-background-color: \"#FCFCFC\"\n      data-background-image: Images/melo.svg\n      data-background-opacity: \"0.75\"\n      data-background-size: auto 80%\n      data-background-position: 90% center\neditor_options: \n  chunk_output_type: console\nnocite: \"@*\"\n---\n\n\n\n\n## Outline {.ai .dark .columns background-image=\"Images/AI/Steps-Spiral.jpg\" background-position=\"right\" background-size=\"auto 100%\"}\n\n::: {.column width=\"50%\"}\n-   [Background](#section-1)\n\n-   [Data and Methods](#section-2)\n\n-   [Results](#section-3)\n\n-   [Outlook and Summary](#section-4)\n:::\n\n::: {.column width=\"50%\"}\n:::\n\n# Research Objective  {.center .middle #aim}\n\nTo examine ***melanoma survival*** and ***trend*** by tumour thickness in overall and in important subgroups such as *sex* and *age* in a unique nationwide case series over a 35-year time period.\n\n# Background {.center .middle .huge background-color=\"#767676FF\"}\n\n## Data from Cancer Registry of Norway (CRN) {.middle}\n\n::: {.columns .grid}\n::: {.column style=\"font-size: 120%;\"}\n::: {.callout-note icon=\"false\" appearance=\"minimal\"}\n*Histologically verified* data\n:::\n::: {.callout-note icon=\"false\" appearance=\"minimal\"}\n*Tumour thickness* recorded since 1980 are *now digitized*\n:::\n::: {.callout-note icon=\"false\" appearance=\"minimal\"}\n*Melanoma registry* established in 2008 under CRN provides the data\n:::\n::: {.callout-tip icon=\"false\" appearance=\"minimal\"}\nHere we will use data from *1983 to 2019*\n:::\n:::\n\n::: {.column}\n![](Images/Logos/CRN-Logo-NoText.svg){fig-align=\"right\"}\n:::\n:::\n\n## Melanoma and tumour thickness \n\n### T-categories\n\n![Source: `https://www.cancerresearchuk.org/about-cancer/melanoma/stages-types/tnm-staging`](Images/T-Stages.svg){width=\"100%\" fig-align=\"center\"}\n\n<!--\n::: {.absolute .fragment .fade-in-then-out .fade-out data-id=\"box1\" style=\"border: 2px solid #800000; width: 130px; height: 90px; margin: 10px; background: #80000011; border-radius: 10%;\" top=\"18%\" left=\"30%\"}\n:::\n\n::: {.absolute .fragment .fade-right .fade-in-then-out data-id=\"box1\" style=\"border: 2px solid #800000; width: 130px; height: 90px; margin: 10px; background: #80000022; border-radius: 10%;\" top=\"18%\" left=\"42%\"}\n:::\n\n::: {.absolute .fragment .fade-right .fade-in-then-out data-id=\"box1\" style=\"border: 2px solid #800000; width: 130px; height: 90px; margin: 10px; background: #80000033; border-radius: 10%;\" top=\"18%\" left=\"57%\"}\n:::\n\n::: {.absolute .fragment .fade-right .fade-in-then-out data-id=\"box1\" style=\"border: 2px solid #800000; width: 130px; height: 90px; margin: 10px; background: #80000044; border-radius: 10%;\" top=\"18%\" left=\"70%\"}\n:::\n-->\n\n# Case series {.center .middle .huge background-color=\"#155F83FF\"}\n\n## Basic characteristics of data {background-transition=\"none\" transition=\"none\" background-image=\"Images/Characteristics-Age.PNG\" background-size=\"90% auto\" background-position=\"center 80%\"}\n\n::: {.callout-note icon=\"false\"}\n### Age at diagnosis\n\nAge at diagnosis has increased in the recent period (2008--2019).\n:::\n\n## Basic characteristics of data {background-transition=\"none\" transition=\"none\" background-image=\"Images/Characteristics-Thickness.PNG\" background-size=\"90% auto\" background-position=\"center 80%\"}\n\n::: {.callout-note icon=\"false\"}\n### Tumour thickness\n\nThe thickness of tumour at diagnosis has decreased in the recent period (2008--2019).\n:::\n\n# Results and Methods  {.center .middle .huge background-color=\"#3E3E23\"}\n\n\n::: {.cell}\n\n:::\n\n\n# Relative Survival {.center .middle background-color=\"#FCFDE5\"}\n\nA way of _comparing the survival_ of people who have melanoma with those who don't, over a certain period of time.\n\n## Relative survival {.smaller .middle}\n\n::: {.columns .grid style=\"grid-template-columns: 1fr 2fr; align-items: end;\"}\n::: column\n\n**By sex and T category**\n\n::: {.callout-note appearance=\"simple\" icon=\"false\"}\nPatients with thinner melanoma (T1) have similar survival as general population.\n:::\n\n::: {.callout-note appearance=\"simple\" icon=\"false\"}\nThe 5-year survival for patients with T4 melanoma is less than 60%\ncompared to general population.\n:::\n\n::: {.callout-note appearance=\"simple\" icon=\"false\"}\nMen have lower survival compared to women in all T-categories.\n:::\n\n::: {.callout-note appearance=\"simple\" icon=\"false\"}\nClear difference in survival by T-categories reflects the importants\nof tumour thickness in prognosis.\n:::\n\n:::\n::: column\n![](plots/surv-by-sex-tstage-ci.svg){width=\"100%\"}\n:::\n:::\n\n## Relative survival {.smaller .middle}\n\n::: {.columns .grid style=\"grid-template-columns: 1fr 2fr; align-items: end;\"}\n::: column\n\n**By sex and T category**\n**Before and After 2000**\n\n::: {.callout-note appearance=\"simple\" icon=\"false\"}\nChanges in long-term survival of T1 and T3 melanoma diagnosed from 2000 is larger in men than in women compared to those diagnosed before 2000.\n:::\n\n::: {.callout-note appearance=\"simple\" icon=\"false\"}\nIn T4 melanoma, only small change is observed in men.\n:::\n\n:::\n::: column\n![](plots/surv-by-sex-tstage.svg){width=\"100%\"}\n:::\n:::\n\n# Cumulative Mortality {.center .middle background-color=\"#FCFDE5\"}\n\nThe proportion (percentage) of a population died because of melanoma over a specified time period.\n\n## Cumulative Mortality {.smaller .middle}\n\n::: {.columns .grid style=\"grid-template-columns: 1fr 2fr; align-items: end;\"}\n::: column\n\n**By sex and T category**\n\n::: {.callout-note appearance=\"simple\" icon=\"false\"}\nIn melanoma patients with T1 tumour, the proportion of dying from melanoma \nis similar to dying from other cause.\n:::\n\n::: {.callout-note appearance=\"simple\" icon=\"false\"}\nThe difference in the proportion of melanoma patients dying from melanoma compared\nto dying from other disease grows as tumour thickness increases.\n:::\n\n::: {.callout-note appearance=\"simple\" icon=\"false\"}\nMen have poor prognosis compared to women (high cumulative incidence).\n:::\n\n:::\n::: column\n![](plots/cuminc-by-sex-tstage.svg){width=\"100%\"}\n:::\n:::\n\n## Is this the effect of treatment? {.smaller .middle}\n\n::: {.columns .grid style=\"grid-template-columns: 1fr 2fr; align-items: end;\"}\n\n::: column \n\n**Melanoma with distant metastasis**\n\n::: {.callout-tip appearance=\"simple\" icon=\"false\"}\nComparing cumulative incidence within distant metastasis cases diagnosed between 2008--2013 and 2014--2019, we observed a drop in melanoma specific deaths in the later period.\n:::\n\n::: {.callout-note appearance=\"simple\" icon=\"false\"}\nAround year 2014, new treatment immunotherapy was introduced in stage IV melanoma.\n:::\n\n:::\n::: column\n![](plots/cuminc-treatment-effect.svg){width=\"100%\"}\n:::\n:::\n\n# Conditional Relative Survival {.center .middle background-color=\"#FCFDE5\"}\n\nRelative survival of a melanoma patients surviving a certain number of year (y) _given that the patients has already survived_ a fixed number of years (x) since diagnosis.\n\n## {.smaller .middle}\n\n::: {.columns .grid style=\"grid-template-columns: 1fr 2fr; align-items: end;\"}\n::: column\n### Conditional 5-year Relative Survival\n\n::: {.callout-info appearance=\"simple\" icon=\"false\"}\nThe dashed line represents the 5 and 10-year relative survival after the patients survived for 0, 1, 2, 3, ... years (scale in grey color). \n:::\n\n::: {.callout-note appearance=\"simple\" icon=\"false\"}\nWe see that in all T-categories, both 5-year and 10-year relative survival condition on surviving certain number of years starts to becomes similar when the conditional year increases.\n:::\n\n::: {.callout-note appearance=\"simple\" icon=\"false\"}\nFor example, two patients diagnosed with T1 and T3 melanoma respectively have similar 5-year relative survival after surviving from 15 years.\n:::\n\n:::\n::: column\n![](plots/cond-surv-by-sex-tstage-crn.svg){width=\"100%\"}\n:::\n:::\n\n# Trend in relative survival {.center .middle background-color=\"#FCFDE5\"}\n\nChanges in relative survial over time.\n\n## Relative turvival Trend {.smaller .middle}\n\n::: {.columns .grid style=\"grid-template-columns: 1fr 2fr; align-items: end;\"}\n::: column\n\n**Relative survival**\n\n**10-years follow-up**\n\n::: {.callout-note appearance=\"simple\" icon=\"false\"}\nThe 10-year relative survival in all T-categories has stable or slight increasing trend. \n:::\n\n::: {.callout-note appearance=\"simple\" icon=\"false\"}\nIn the case of thicker melanoma, women have higher increasing trend in T4 melanoma and men have in T3.\n:::\n:::\n\n::: column\n![](plots/trend-by-sex-tstage-llm.svg){width=\"100%\"}\n:::\n:::\n\n# Wrap-up {.center .middle .huge background-color=\"#642822\"}\n\n## Summary {.ai .dark background-image=\"Images/AI/Overview-Lake-Boat.jpg\" background-position=\"right\" background-size=\"auto 100%\"}\n\n::: columns\n::: {.column width=\"50%\" style=\"font-size: 85%;\"}\n::: {.callout-note appearance=\"simple\" icon=\"false\"}\n-   Despite _stable melanoma mortality_ was seen in cancer reports in Norway for last few years, Norway _ranks second in mortality_ worldwide.\n:::\n::: {.callout-important appearance=\"simple\" icon=\"false\"}\n-   Older men diagnosed more with _thicker melanoma_ and has _higher mortality_\n:::\n\n::: {.callout-tip appearance=\"simple\" icon=\"false\"}\n-   Awareness focused on *elderly males* may be effective for *early detection*.\n-   _Risk stratification_ and _targeted_ screening\n:::\n:::\n\n::: {.column width=\"50%\"}\n:::\n:::\n\n# {visibility=\"hidden\"}\n\n##  {#logo-profile .center .smaller}\n\n::: columns\n::: {.column width=\"30%\"}\n### Collaborators\n\n::: collab-logo\n![](Images/Logos/UiO-Logo.png){#uio width=\"100%\"} ![](Images/Logos/CRN-Logo.svg){#crn width=\"100%\"} ![](Images/Logos/QIMR-Logo.png){#qimr width=\"100%\"} ![](Images/Logos/IARC-Logo.png){#iarc width=\"100%\"} ![](Images/Logos/OCBE-Logo.png){#ocbe width=\"100%\"} ![](Images/Logos/OUS-Logo.png){#ous width=\"100%\"} ![](Images/Logos/RNF-Logo.svg){#rnf width=\"100%\"}\n:::\n:::\n\n::: {.column width=\"70%\"}\n### Coauthors\n\n::: profile-container\n\n::: {.profile-card}\n![](Images/Profile/01-profile-raju-rimal.png){width=\"100%\"}\n<p>Raju Rimal</p>\n:::\n::: {.profile-card}\n![](Images/Profile/02-profile-trude-e-robsahm.png){width=\"100%\"}\n<p>Trude E Robsahm</p>\n:::\n::: {.profile-card}\n![](Images/Profile/03-profile-adele-green.png){width=\"100%\"}\n<p>Adele Green</p>\n:::\n::: {.profile-card}\n![](Images/Profile/04-profile-reza-ghiasvand.png){width=\"100%\"}\n<p>Reza Ghiasvand</p>\n:::\n::: {.profile-card}\n![](Images/Profile/05-profile-corina-s-rueegg.png){width=\"100%\"}\n<p>Corina S Rueegg</p>\n:::\n::: {.profile-card}\n![](Images/Profile/06-profile-assia-bassarova.png){width=\"100%\"}\n<p>Assia Bassarova</p>\n:::\n::: {.profile-card}\n![](Images/Profile/07-profile-petter-gjersvik.png){width=\"100%\"}\n<p>Petter Gjersvik</p>\n:::\n::: {.profile-card}\n![](Images/Profile/08-profile-elisabete-weiderpass.png){width=\"100%\"}\n<p>Elisabete Weiderpass</p>\n:::\n::: {.profile-card}\n![](Images/Profile/09-profile-odd-o-aalen.png){width=\"100%\"}\n<p>Odd O Aalen</p>\n:::\n::: {.profile-card}\n![](Images/Profile/10-profile-bjÃ¸rn-mÃ¸ller.png){width=\"100%\"}\n<p>BjÃ¸rn MÃ¸ller</p>\n:::\n::: {.profile-card}\n![](Images/Profile/11-profile-marit-b-veierÃ¸d.png){width=\"100%\"}\n<p>Marit B VeierÃ¸d</p>\n:::\n\n:::\n\n::: {style=\"text-align:center; width:100%; color:firebrick;\"}\nFunded by: The Research Council of Norway.\n:::\n:::\n:::\n\n##  {background-image=\"Images/Thank-You.png\" background-size=\"auto 90%\"}\n\n## References {.smaller}\n\n::: {#refs}\n:::\n",
    "supporting": [
      "index_files"
    ],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {
      "include-after-body": [
        "\n<script>\n  // htmlwidgets need to know to resize themselves when slides are shown/hidden.\n  // Fire the \"slideenter\" event (handled by htmlwidgets.js) when the current\n  // slide changes (different for each slide format).\n  (function () {\n    // dispatch for htmlwidgets\n    function fireSlideEnter() {\n      const event = window.document.createEvent(\"Event\");\n      event.initEvent(\"slideenter\", true, true);\n      window.document.dispatchEvent(event);\n    }\n\n    function fireSlideChanged(previousSlide, currentSlide) {\n      fireSlideEnter();\n\n      // dispatch for shiny\n      if (window.jQuery) {\n        if (previousSlide) {\n          window.jQuery(previousSlide).trigger(\"hidden\");\n        }\n        if (currentSlide) {\n          window.jQuery(currentSlide).trigger(\"shown\");\n        }\n      }\n    }\n\n    // hookup for slidy\n    if (window.w3c_slidy) {\n      window.w3c_slidy.add_observer(function (slide_num) {\n        // slide_num starts at position 1\n        fireSlideChanged(null, w3c_slidy.slides[slide_num - 1]);\n      });\n    }\n\n  })();\n</script>\n\n"
      ]
    },
    "engineDependencies": {},
    "preserve": {},
    "postProcess": true
  }
}